866-997-4948(US-Canada Toll Free)

Abdominal Obesity - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 40 Pages


Global Markets Directs, \'Abdominal Obesity Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Abdominal Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abdominal Obesity. Abdominal Obesity Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Abdominal Obesity.
  • A review of the Abdominal Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Abdominal Obesity pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Abdominal Obesity.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Abdominal Obesity pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Abdominal Obesity Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Abdominal Obesity 7
Abdominal Obesity Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Abdominal Obesity Therapeutics - Products under Development by Companies 12
Companies Involved in Abdominal Obesity Therapeutics Development 13
Theratechnologies Inc. 13
Aileron Therapeutics, Inc. 14
Lithera, Inc. 15
Abdominal Obesity - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
tesamorelin acetate - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(fluticasone propionate + salmeterol xinafoate) - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ALRN-5281 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
salmeterol xinafoate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Abdominal Obesity Therapeutics - Drug Profile Updates 29
Abdominal Obesity - Product Development Milestones 33
Featured News & Press Releases 33
Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia 33
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 33
Apr 02, 2013: Lithera Receives Patent From USPTO Protecting Methods Of Use And Formulations For LIPO-202 34
Mar 12, 2013: Lithera Initiates Phase IIb Clinical Trial Of LIPO-202 Targeting Aesthetic Reduction Of Subcutaneous Abdominal Fat 34
Feb 26, 2013: Aileron Therapeutics To Highlight Stapled Peptide Pipeline At 2013 AsiaTIDES Meeting 35
Jan 21, 2013: Theratechnologies Announces FDA Approval Of Alternative Storage Conditions For Egrifta 36
Sep 06, 2012: Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C Chen As Vice President of Clinical Development 36
Jun 26, 2012: Ferrer Withdraws Marketing Authorization Application For Egrifta 37
Sep 06, 2011: GENFIT Publishes GFT505 Clinical Trial Results In Diabetes Care 37
Dec 06, 2010: Theratechnologies Announces A Distribution And Licensing Agreement For Egrifta In Latin America, Africa And The Middle East With Sanofi-aventis 37

Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Table


Number of Products Under Development for Abdominal Obesity, H2 2013 7
Products under Development for Abdominal Obesity - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Theratechnologies Inc., H2 2013 13
Aileron Therapeutics, Inc., H2 2013 14
Lithera, Inc., H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Assessment by Combination Products, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 21
Abdominal Obesity Therapeutics - Drug Profile Updates 29

List of Chart


Number of Products under Development for Abdominal Obesity, H2 2013 7
Products under Development for Abdominal Obesity - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 16
Assessment by Combination Products, H2 2013 17
Assessment by Route of Administration, H2 2013 18
Assessment by Stage and Route of Administration, H2 2013 19
Assessment by Molecule Type, H2 2013 20
Assessment by Stage and Molecule Type, H2 2013 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *